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STUDY PROTOCOL Open Access
Project HELP: a study protocol to pilot
test a shared decision-making tool about
treatment options for patients with
hepatitis C and chronic kidney disease
M. C. Politi1*, N. George1, T. Li2†, K. M. Korenblat3†, K. J. Fowler4†, C. Ho5†, A. Liapakis6†, D. Roth7† and J. Yee8†
Abstract
Background: Recent advances in treatment have given patients with chronic kidney disease (CKD) access to safer
and more effective medications to treat comorbid hepatitis C virus (HCV) infection. Given the variety and complexity
of treatment options that depend on patients’ clinical characteristics and personal preferences, education and decision
support are needed to prepare patients better to discuss treatment options with their clinicians.
Methods: Drawing on International Patient Decision Aids Standards guidelines, literature reviews, and guidance from a
diverse expert advisory group of nephrologists, hepatologists, and patients, we will develop and test a HCV and CKD
decision support tool. Named Project HELP (Helping Empower Liver and kidney Patients), this tool will support patients
with HCV and CKD during decisions about whether, when, and how to treat each illness. The tool will (1) explain
information using plain language and graphics; (2) provide a step-by-step process for thinking about treating HCV and
CKD; (3) tailor relevant information to each user by asking about the individual’s stage of CKD, stage of fibrosis, prior
treatment, and comorbidities; (4) assess user knowledge and values for treatment choices; and (5) help individuals use
and consider information appropriate to their values and needs to discuss with a clinician. A pilot study including 70
individuals will evaluate the tool’s efficacy, usability, and likelihood of using it in clinical practice. Eligibility criteria will
include individuals who understand and read English, who are at least 18 years old, have a diagnosis of HCV
(any genotype) and CKD (any stage), and are considering treatment options.
Discussion: This study can identify particular characteristics of individuals or groups that might experience
challenges initiating treatment for HCV in the CKD population. This tool could provide a resource to facilitate
patient-clinician discussions regarding HCV and CKD treatment options.
Keywords: Hepatitis C, Chronic kidney disease, Patient centered, Decision aids, Decision support, Health communication
Background
Hepatitis C virus (HCV) infection is a chronic, debilitating
disease that affects 170 million people globally and about
3.9 million individuals in the USA [1]. This public health
issue is the most common blood-borne illness in the USA
[2] and is especially prevalent among those with chronic
kidney disease (CKD). The estimated prevalence of HCV
in hemodialysis patients in the USA is 8.6% [2], almost five
times greater than in the general US population [3].
Individuals with untreated HCV can develop serious com-
plications including cirrhosis, liver failure, and/or hepato-
cellular carcinoma [4].
Among patients with CKD, the presence of HCV can
significantly affect their quality of life and health
outcomes. Patients with CKD who also have chronic
HCV infection may have an increased risk of death,
hospitalization, loss of kidney function, and kidney
transplant failure [4–10]. HCV infection has been asso-
ciated with lower quality of life in patients on dialysis
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and may be particularly adverse to patients’ mental
health [11]. The goal of therapy for chronic HCV
infection is a sustained virologic response (SVR)
where the disease is undetectable 12 to 24 weeks fol-
lowing discontinuation of therapy [12]. SVR reduces
the chance of cirrhosis of the liver, liver cancer, the
need for liver transplantation, and overall death rates
among patients with CKD [13–16]. As a result, na-
tional and international guidelines suggest that HCV-
infected patients with CKD should consider antiviral
treatment for their HCV [17].
In the past, few patients with CKD received treatment
for their HCV infection despite the potential benefits
[18]. Early medications for HCV infection included
interferon-based therapies in combination with ribavirin.
These drugs were not always effective, eliminating HCV
from only 14 to 63% of patients [19]. Many patients ex-
perienced severe side effects and reduced their doses or
discontinued treatment on these medications [20, 21].
Because side effects such as anemia were amplified in
patients with CKD, treating HCV in CKD patients was
especially challenging, and many patients with CKD and
their clinicians felt that the potential benefits of treat-
ment might not outweigh the potential risks. As a result,
as few as 1% of HCV+ CKD patients were prescribed
antiviral medications [2].
Over the past 4 years, oral direct-acting antiviral
(DAA) agents, molecules that target specific nonstruc-
tural proteins of the virus and interrupt HCV viral repli-
cation have become available as treatment options for
patients with HCV infection [22]. DAA regimens have a
higher SVR (> 95%) and relatively few toxicities com-
pared to previous treatments [23, 24]. They also have
easier dosing regimens and fewer interactions with other
medications used to treat patients with comorbidities
[25]. There are now DAA regimens FDA approved for
patients with a creatinine clearance < 30 ml/min. Studies
suggest that patients with severe renal impairment toler-
ate treatment with DAAs well, and have many positive
outcomes from these medications [26, 27].
With these advances in therapeutic options, patients
with both HCV and CKD now face different complex
decisions. The primary decision is the timing of HCV
therapy, especially for renal-impaired patients [14, 17].
Successful anti-viral therapy can halt the progression of
liver fibrosis, reduce the risk of hepatocellular carcin-
oma, improve quality of life, and even potentially reduce
the risk of progression of CKD [22, 28]. However, delay-
ing therapy may allow patients to consider acceptance of
a kidney allograft from a HCV viremic donor and allow
for early access to transplant, reduced time on dialysis,
and a reduction in the associated mortality of renal re-
placement therapy. Specifics of the DAA regimens (i.e.,
dosing, labeling in end-organ disease or organ damage
due to disease progression, and cost) as well as drug-
drug interactions need to be considered [17, 22].
Occasionally, among those with multiple comorbidities
and severe CKD, patients must consider whether HCV
treatment would improve their quality of life. Patients and
clinicians should weigh these complexities in treatment
options and timing; tailored decision tools may help guide
patients and clinicians through this decision process. Cli-
nicians often use management paradigms to guide their
assessment for each patient’s case [29]. With the recent in-
crease in the use of kidneys from HCV-infected donors
for transplants, there is a potential to generate positive
health outcomes for vulnerable populations with advanced
CKD and HCV [30]. However, not all patients are good
candidates for kidney transplantation.
Patients’ subjective preferences for the tradeoffs be-
tween potential benefits and harms of treatment options
can impact choices. Patients’ insurance coverage and po-
tential out-of-pocket costs can also affect their access
and adherence to treatment [31]. To make treatment de-
cisions, patients must balance each of these factors, as
well as advice from multiple clinicians, including ne-
phrologists, hepatologists, and sometimes a primary care
provider. Given the variety and complexity of treatment
options that depend on patients’ clinical characteristics
and personal preferences, interventions are needed to
better prepare patients to discuss options with clinicians.
Patient decision aids are designed to help patients under-
stand complex health options and take an active role in
decision-making. Decision aids differ from educational ma-
terials because of their detailed, precise, and personalized
focus on options, outcomes, probabilities, and patients’
values. Decision aids have been shown to reduce decisional
conflict, increase patient’s knowledge of treatment options,
lower decision regret, increase patient involvement in deci-
sions, reduce patient indecision concerning treatment, and
increase the probability that treatment decisions will be
consistent with patients’ values [32].
This study, called Project HELP (Helping Empower
Liver and kidney Patients), will develop and test a web-
based decision aid to support patients with HCV and
CKD during decisions about whether, when, and how to
treat each illness. Patients will also have the opportunity
to learn about their hepatitis C and kidney disease, initi-
ate thought about what matters most to them and
choose a treatment plan for their liver and kidney dis-
ease that works best for them. This decision aid will:
1. Explain information using plain language and
graphics [see Fig. 1] and provide a step-by-step
process for thinking about treating HCV and CKD
2. Tailor relevant information to each user by asking
about the user’s stage of CKD, stage of fibrosis, prior
treatment, and comorbidities
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3. Assess user knowledge and values for treatment
choices
4. Help individuals use and consider information
appropriate to their values and needs [see Fig. 1]
by creating a summary page that displays values
that users should discuss with their clinician before
starting treatment
This web-based tool will not replace a conversation
with a clinician; it will be used to prepare patients for
visits with a clinician. This manuscript describes the
process for developing the Project HELP decision aid
and our study protocol for pilot testing the tool.
Methods
The content for this decision aid will be based on
literature reviews and guidance from a diverse expert
advisory group consisting of three nephrologists, three
hepatologists, and two patients. Clinicians represent six
different practices in four US regions (West, Midwest,
Northeast, and Southeast). The content will be written
at a sixth-grade reading level. The preliminary content
of the decision aid will be based on Kidney Disease:
Improving Global Outcomes (KDIGO) guidelines [17],
the joint American Association for the Study of Liver
Disease- Infectious Disease Society of America’s [22]
combined guidelines and graded evidence, and our
advisory board feedback.
First, the tool will assess individual factors that could
impact HCV and CKD outcomes such as CKD severity,
HCV genotype, stage of fibrosis, prior treatment history,
and comorbidities. Based upon the answers to each
question, the tool will provide tailored information and
feedback to patients regarding these outcomes. Next,
patients will be given a brief overview of HCV, CKD, the
health effects of both diseases, and treatment options for
both HCV and CKD. The decision aid will then review
users’ knowledge of the content they received by asking
eight review questions, providing immediate feedback as
they answer the questions. Patients will rate what
matters most to them as they weigh their treatment
decisions. Patients will be able to select or enter
questions to ask a provider about HCV and CKD. A
summary page will be generated at the end of the
participant’s session that can be saved or printed to
access when talking to a clinician. The tool will follow
International Patient Decision Aids Standards guidelines
for decision tool development across applicable sections
[33]. The tool will be developed over the course of 6–
10 months and will include evidence synthesis, expert
advisory board review, patient advisory review, readabil-
ity assessment to ensure comprehension across literacy
levels, and pilot testing sections of the tool for usability
prior to the study beginning.
A pilot study of the tool will include 70 individuals.
Eligibility criteria will include those who read and under-
stand English, who are at least 18 years old and have a
diagnosis of HCV (any genotype) and CKD of any stage.
Recruitment will occur from October 2017 to May
2018.The research coordinator will screen medical re-
cords for eligible patients in our CKD clinics, dialysis
units, and transplant clinics. Participants will have the
Fig. 1 Screenshots from Project HELP decision tool. The left screenshot is an example of the plain language education. The Let’s Explore What
Matters to You section allows participants to consider their values about treating their hepatitis C. Other sections are described in this paper and
shown in the menu bar
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choice to complete the study surveys using a web or
paper-based version depending on their preference. The
participant will be able to complete the study in person
on a computer or tablet provided by us or at home. Par-
ticipation requires approximately 30 min. Participants
will receive a $20 gift card as compensation for their
time. Figure 2 shows a study flow chart; we will
follow MSD’s Guidelines for Publication of Clinical
Trials in the Scientific Literature. This study is
approved by the Human Research Protection Office
(HRPO) at Washington University in St. Louis.
Measures
Our primary outcome measures will include patients’
HCV and CKD knowledge, decisional conflict, decision
self-efficacy, and the decision aid’s usability. To measure
patients’ knowledge, we will develop items based on in-
formation that is considered vital to making treatment
decisions, understanding what is HCV and CKD, the
health effects of both diseases, and understanding facts
that differentiate treatment options [34]. The response
options will include true/false/unsure. The total number
of correct responses will be calculated, with 1 point
given for each correct response and 0 for unsure or
incorrect responses. We will pilot test the items with
patients before and after the study. We will calculate
Cronbach’s alpha to assess the internal consistency of
our questions.
To assess decisional conflict, we will administer the 4-
item SURE Test version of the Decisional Conflict Scale
(DCS) [35]. This scale measures whether individuals feel
they have enough information to make a choice, are
clear about their values for risks and benefits of their
choice, and feel they have enough support to make a
choice. Items will be scored as 1 (yes) or 0 (no).
To measure decision self-efficacy, we will use the
lower literacy version of the Decision Self-Efficacy Scale
[36]. This scale is a validated measure of an individual’s
Fig. 2 Aim 2—pilot-test study flow diagram
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self-confidence or belief in their ability to make a deci-
sion. Individuals will be asked to rate on a three-item
scale how confident they feel taking actions involved in
making an informed choice (e.g., gathering information,
asking questions, and expressing opinions). This scale
has high levels of internal consistency (mean Cronbach’s
alpha = 0.86) [28] and correlates with feeling informed,
supported, and knowledgeable about decisions.
To assess usability, we will use the 10-item System
Usability Scale (SUS) [37], a reliable, validated scale for
evaluating the usability of our website. Secondary out-
comes and potential covariates include factors that could
influence decisions and quality of life such as clinical
characters (e.g., CKD severity, stage of liver fibrosis,
HCV genotype, prior treatment history of HCV and
length of diagnosis, and comorbidities), demographics,
health literacy [38], patients’ preferred decision role, and
financial toxicity [39].
Data analysis plan
Descriptive statistics will be calculated for all variables.
Data will be examined for within group differences in
outcomes (knowledge, decisional conflict, decision self-
efficacy) among patients pre- and post-use of the DA in
a multivariable linear regression model controlling for
up to 5 independent covariates (e.g., age, stage of liver
fibrosis, health literacy, CKD stage, and prior history of
HCV treatment). We will include knowledge, decisional
conflict, and decision self-efficacy as primary outcomes
in three separate multivariable models, controlling for
age and stage of liver fibrosis. Health literacy will be
included as a covariate in the model with knowledge as
an outcome. We will explore whether differences exist
based upon CKD stage by including it as a covariate in
our analyses. Prior history of HCV treatment will be
included as a covariate in the model with knowledge as
an outcome.
Discussion
Many patients depend on their doctors to supply enough
information to help facilitate treatment decisions. How-
ever, HCV and CKD treatment decisions for patients
with both conditions are complex and can be over-
whelming. Many patients want to participate actively in
the shared decision-making process and be well-
informed consumers and contributors of their own
healthcare [40]. Decision aids can assist patients with
understanding their choices, tailored to their specific
needs and preferences. These tools can be used before,
during, or after meeting with a clinician depending on
clinic flow and patient preferences.
To our knowledge, tools that have been developed
about HCV and CKD treatment choices have been for
clinician use only. Our tool will be the first tool for pa-
tients and clinicians to use together that accounts for
the unique needs of this population. After patients use
our tool, they will be able to save or print a summary
page that they can share and discuss with their clinicians
during their visit to take a more active role in treatment
decisions. Using this tool will potentially allow patients
with chronic HCV infection and CKD to make an
informed treatment decision and increase the rates of
personalized treatment approaches.
Strengths of the study include personalized decision
support tailored to patients’ clinical needs, the use of
International Patient Decision Aids Standards guidelines
for decision tool development, and the inclusion of an
advisory group which consists of both clinicians and
Fig. 3 Project HELP—overall study objectives
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patients to help guide the development of the study and
decision tool itself. Given that this is a pilot study, we
will not know for sure whether our sample size is large
enough to detect differences, but we selected our study
design (pre-post within-subjects study design) and
targeted sample size based on past studies demonstrat-
ing a small to medium effect size for most outcomes.
After the study, we will conduct post-hoc power calcula-
tions to determine actual effect sizes to better plan for
future, larger studies. This project is a single-site study
with a moderate sample size, so results might not be
generalizable. To address this, we plan to include a
national sample of clinicians for our semi-structured
qualitative interviews, which will be conducted as part of
the next aim of this study (see Fig. 3).
Because there is no use of randomization, results
should be interpreted as demonstrating the preliminary
efficacy of the tool. We considered randomizing patients
to the decision tool or a control group of usual care, but
randomizing at the patient level could bias clinicians’
discussions with patients in the control or usual care
group. Our pilot study is not equipped to conduct a
multi-site trial randomizing at the provider or clinic
level. This study can identify particular characteristics of
individuals or groups that might experience challenges
initiating treatment for HCV in the CKD population.
This tool could provide a resource to facilitate patient-
clinician discussions regarding HCV and CKD treatment
options. We plan to conduct semi-structured qualitative
interviews with both clinicians and participants after this
pilot evaluation of the decision aid to gather feedback
about implementing the tool into clinical practice
beyond the duration of this proposal.
Future plans
We will continue to work closely with our advisory
board, patients, and clinicians to plan for subsequent
studies and implementation. We will develop electronic
communication strategies and disseminate our tool
nationwide through multiple channels to maximize the
usefulness of these findings in ongoing clinical prac-
tice and research efforts. Future larger studies could
conduct a randomized trial comparing the tool to
usual care, randomizing at the clinic level to account
for the individualized approach clinicians may use
when treating their patients.
Abbreviations
CKD: Chronic Kidney Disease; DAAs: Direct-acting antivirals; FDA: Food and
Drug Administration; HCV: Hepatitis C virus; SVR: Sustained virologic response
Acknowledgements
We would like to thank John Terry for his contributions to the study.
Funding
Funding for this research was provided by Merck & Co., Inc., Kenilworth, NJ USA.
Availability of data and materials
Not Applicable.
Authors’ contributions
MCP is the PI of the study, leading the study design, tool development, project
implementation, and writing of this manuscript. NG contributed to the
development of the decision tool, revised the manuscript, and approved the
manuscript’s final content. TL and KK are co-investigators for the study
and contributed to the development of the decision tool, revised the
manuscript, and approved the manuscript’s final content. KJF, CH, AL, DR
and JY are all members of the study’s expert advisory group and contributed to
the development of the decision tool, revised the manuscript, and approved
the manuscript’s final content.
Ethics approval and consent to participate
This study is approved by the Human Research Protection Office (HRPO) at
Washington University in St. Louis protocol number 2017707154.
Consent for publication
Not Applicable.
Competing interests
MCP has a research contract (2017–2019) funded by Merck & Co., Inc., Kenilworth,
NJ, USA, and previously received a speaker fee from Merck & Co, Inc., Kenilworth,
NJ, USA. KJF has recently consulted for Protalix, Hansa Medical, Horizon Pharma
Inc., TapCloud LLC, and Merck & Co, Inc., Kenilworth, NJ, USA. DR has served on
advisory boards for Bristol-Myers Squibb and Merck & Co, Inc., Kenilworth, NJ, USA.
CH, AL, and JY consult for a research study funded by Merck & Co, Inc., Kenilworth,
NJ, USA. The other authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Division of Public Health Sciences, Department of Surgery, Washington
University in St. Louis School of Medicine, 660 S. Euclid Ave., Campus Box
8100, St. Louis, MO 63110, USA. 2Department of Internal Medicine, Division of
Nephrology, Washington University School of Medicine, 660 S. Euclid Ave.,
Campus Box 8129, St. Louis, MO 63110, USA. 3Department of Internal
Medicine, Division of Gastroenterology, Washington University School of
Medicine, 660 S. Euclid Ave., Campus Box 8124, St. Louis, MO 63110, USA.
4The Voice of the Patient Inc., 908 South Cambridge Ave., Elmhurst, IL 60126,
USA. 5California Pacific Medical Center, 2340 Clay Street, 3rd floor, San
Francisco, CA 94115, USA. 6Department of Internal Medicine Section of
Digestive Disease, Yale University School of Medicine, 333 Cedar St., PO Box
208019, New Haven, CT 06520, USA. 7Katz Family Division of Nephrology and
Hypertension, University of Miami Miller School of Medicine, 120 NW 14th St.
Room 813, Miami, FL 33136, USA. 8Division Head of Nephrology,
Hypertension & Transplant, Henry Ford Hospital and Medical Center, 2799
West Grand Blvd, CFP-514, Detroit, MI 48202-2689, USA.
Received: 1 November 2017 Accepted: 14 February 2018
References
1. Centers for Disease Control and Prevention. Hepatitis C FAQs for Health
Professionals. 2017. Available from: https://www.cdc.gov/hepatitis/hcv/
hcvfaq.htm#a1.
2. Goodkin DA, et al. Hepatitis C infection is very rarely treated among
hemodialysis patients. Am J Nephrol. 2013;38(5):405–12.
3. Patel PR, et al. Epidemiology, surveillance, and prevention of hepatitis C
virus infections in hemodialysis patients. Am J Kidney Dis. 2010;56(2):371–8.
4. Fabrizi F, et al. Hepatitis C virus infection and kidney disease: a meta-
analysis. Clin J Am Soc Nephrol. 2012;7(4):549–57.
5. Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J
Kidney Dis. 2011;57(3):396–402.
6. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis
patients: a link with cardiovascular mortality? J Viral Hepat. 2012;19(9):601–7.
Politi et al. Pilot and Feasibility Studies  (2018) 4:55 Page 6 of 7
7. Goodkin DA, et al. Mortality, hospitalization, and quality of life among
patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol.
2017;12(2):287–97.
8. Noureddine LA, et al. Hepatitis C increases the risk of progression
of chronic kidney disease in patients with glomerulonephritis. Am J
Nephrol. 2010;32(4):311–6.
9. Fabrizi F, et al. Hepatitis C virus antibody status and survival after renal
transplantation: meta-analysis of observational studies. Am J Transplant.
2005;5(6):1452–61.
10. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C
infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol.
2007;2(3):563–75.
11. Afsar B, et al. Quality of life in hemodialysis patients: hepatitis C virus
infection makes sense. Int Urol Nephrol. 2009;41(4):1011–9.
12. Ghany MG, et al. Diagnosis, management, and treatment of hepatitis C: an
update. Hepatology. 2009;49(4):1335–74.
13. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for
chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis.
2011;52(7):889–900.
14. Cacoub P, et al. Hepatitis C virus infection and chronic kidney disease: time
for reappraisal. J Hepatol. 2016;65(1):S82–94.
15. van der Meer AJ. Achieving sustained virological response: what’s the
impact on further hepatitis C virus-related disease? Expert Rev Gastroenterol
Hepatol. 2015;9(5):559–66.
16. Backus LI, et al. A sustained Virologic response reduces risk of all-cause
mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;
9(6):509–16. e1
17. KDIGO, 2017 Clinical Practice Guidelines For The Prevention, Diagnosis,
Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Public
Review Draft. Available from: http://www.kdigo.org/clinical_practice_
guidelines/Hep%20C/KDIGO%202017%20Hep%20C%20GL%20Public%20
Review%20Draft%20FINAL.pdf.
18. Goodkin DA, Bieber B. Hemodialysis patients with hepatitis C infection are not
receiving the new antiviral medications. Am J Nephrol. 2015;41(4–5):302.
19. Feuerstadt P, et al. Effectiveness of hepatitis C treatment with
pegylated interferon and ribavirin in urban minority patients.
Hepatology. 2010;51(4):1137–43.
20. Fried MW, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C
virus infection. N Engl J Med. 2002;347(13):975–82.
21. Manns MP, et al. Peginterferon alfa-2b plus ribavirin compared with
interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a
randomised trial. Lancet. 2001;358(9286):958–65.
22. American Association for the Study of Liver-Infectious Diseases Society of
America. HCV guidance: recommendations for testing, managing, and
treating hepatitis C. 2017. Available from: https://www.hcvguidelines.org/
evaluate.
23. Azmi AN, Tan S-S, Mohamed R. Hepatitis C and kidney disease: an overview
and approach to management. World J Hepatol. 2015;7(1):78–92.
24. Feeney ER and RT Chung. Antiviral treatment of hepatitis C. BMJ. 2014;349:
g3308.
25. Lynch SM, Wu GY. Hepatitis C virus: a review of treatment guidelines, cost-
effectiveness, and access to therapy. J Clin Transl Hepatol. 2016;4(4):310–9.
26. Roth D, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-
experienced patients with hepatitis C virus genotype 1 infection and stage
4–5 chronic kidney disease (the C-SURFER study): a combination phase 3
study. Lancet. 2015;386(10003):1537–45.
27. Gane E, et al. Glecaprevir and pibrentasvir in patients with HCV and severe
renal impairment. N Engl J Med. 2017;377(15):1448–55.
28. Hsu Y-C, et al. Association between antiviral treatment and extrahepatic
outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495–503.
29. Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney
disease. J Am Soc Nephrol. 2016;27(8):2238–46.
30. Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney
disease: advances, limitations and unchartered territories. J Viral Hepat.
2017;24(6):442–53.
31. Millman AJ, et al. Barriers to treatment access for chronic hepatitis C virus
infection: a case series. Top Antivir Med. 2017;25(3):110–3.
32. Stacey D., et al. Decision aids for people facing health treatment or
screening decisions. Cochrane Database Syst Rev. 2017(4):CD001431. https://
doi.org/10.1002/14651858.CD001431.pub5.
33. Elwyn G, et al. International Patient Decision Aids Standards (IPDAS)
collaboration. Developing a quality criteria framework for patient
decision aid: online international Delphi consensus process. Br Med J.
2006;333(7565):417–9.
34. Wolf L. The information needs of women who have undergone breast
reconstruction. Part I: decision-making and sources of information. Eur J
Oncol Nurs. 2004;8(3):211–23.
35. O'Connor AM. Validation of a decisional conflict scale. Med Decis Mak. 1995;
15(1):25–30.
36. O’Connor A., User manual-decision self-efficacy scale. Patient Decision Aids,
Ottawa Hospital Research Institute (OHIR). 1995. Available from: https://
decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decision_SelfEfficacy.pdf.
37. Brooke, J. System usability scale—a quick and dirty usability scale 1986;
Available from: https://www.usability.gov/how-to-and-tools/methods/
system-usability-scale.html.
38. Morris NS, et al. The single item literacy screener: evaluation of a brief
instrument to identify limited reading ability. BMC Fam Pract. 2006;7:21.
39. de Souza JA, et al. Measuring financial toxicity as a clinically relevant
patient-reported outcome: the validation of the COmprehensive Score for
financial Toxicity (COST). Cancer. 2017;123(3):476–84.
40. Barry MJ, Edgman-Levitan S. Shared decision making—the pinnacle of
patient-centered care. N Engl J Med. 2012;366(9):780–1.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Politi et al. Pilot and Feasibility Studies  (2018) 4:55 Page 7 of 7
